Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 0.6984 -0.0248 (-3.43%) Market Cap: 178.71 Mil Enterprise Value: 73.46 Mil PE Ratio: 0 PB Ratio: 2.25 GF Score: 64/100

Adaptimmune Therapeutics PLC to Discuss Completion of Strategic Combination with TCR2 Call Transcript

Jun 02, 2023 / 12:00PM GMT
Release Date Price: $1.08 (-0.92%)
Operator

Hello, and welcome to Adaptimmune Announces closing of Strategic Combination with TCR2. I will now turn the call over to Juli Miller.

Juli, please go ahead.

Juli P. Miller
Adaptimmune Therapeutics plc - VP of IR

Good day, and welcome to our WebEx to discuss completion of our strategic combination with TCR2.

I would ask you to review the full text of our forward-looking statements. We anticipate making projections during this call and actual results could differ materially due to several factors, including those outlined in our latest filings with the SEC. Adrian Rawcliffe, our Chief Executive Officer, is here with me for the prepared portion of the call and will be available for Q&A. With that, I'll turn it over to Adrian. Ad?

Adrian G. Rawcliffe
Adaptimmune Therapeutics plc - CEO, Principal Accounting Officer & Director

Thanks, Juli, and thank you, everyone, for joining us. My comments today are going to be brief, and we can go directly into any questions you have.

I'll start

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot